Patents by Inventor Henning Ralf Stennicke

Henning Ralf Stennicke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Factor VIII variants having a decreased cellular uptake
    Patent number: 10906960
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to modied Factor VIII molecules having decreased cellular uptake.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: February 2, 2021
    Assignee: SANQUIN BLOOD SUPPLY FOUNDATION
    Inventors: Henriet Meems, Alexander Benjamin Meijer, Koenraad Mertens, Ole Hvilsted Olsen, Kasper Lamberth, Peder Lisby Noerby, Laust Bruun Johnsen, Marianne Hjortnes Kjalke, Henning Ralf Stennicke, Johannes Jacobus Voorberg, Maartje Van Den Biggelaar
  • Factor VII conjugates
    Patent number: 10179905
    Abstract: The present invention relates to the conjugation of Factor VII polypeptides with heparosan polymers. The resultant conjugates may be used to deliver Factor VII, for example in the treatment or prevention of bleeding disorders.
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: January 15, 2019
    Assignee: Novo Nordisk Health Care AG
    Inventors: Carsten Behrens, Henrik Oestergaard, Henning Ralf Stennicke
  • Factor VIII Variants Having A Decreased Cellular Uptake
    Publication number: 20180327479
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to modied Factor VIII molecules having decreased cellular uptake.
    Type: Application
    Filed: July 6, 2018
    Publication date: November 15, 2018
    Inventors: Henriet Meems, Alexander Benjamin Meijer, Koenraad Mertens, Ole Hvilsted Olsen, Kasper Lamberth, Peder Lisby Noerby, Laust Bruun Johnsen, Marianne Hjortnes Kjalke, Henning Ralf Stennicke, Johannes Jacobus Voorberg, Maartje Van Den Biggelaar
  • Factor VIII variants having a decreased cellular uptake
    Patent number: 10047142
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to modied Factor VIII molecules having decreased cellular uptake.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: August 14, 2018
    Assignees: Novo Nordisk A/S, Sanquin Blood Supply Foundation
    Inventors: Henriet Meems, Alexander Benjamin Meijer, Koenraad Mertens, Ole Hvilsted Olsen, Kasper Lamberth, Peder Lisby Noerby, Laust Bruun Johnsen, Marianne Hjortnes Kjalke, Henning Ralf Stennicke, Johannes Jacobus Voorberg, Maartje Van Den Biggelaar
  • FACTOR VII CONJUGATES
    Publication number: 20170355974
    Abstract: The present invention relates to the conjugation of Factor VII polypeptides with heparosan polymers. The resultant conjugates may be used to deliver Factor VII, for example in the treatment or prevention of bleeding disorders.
    Type: Application
    Filed: March 8, 2017
    Publication date: December 14, 2017
    Inventors: Carsten Behrens, Henrik Oestergaard, Henning Ralf Stennicke
  • FACTOR VIII VARIANTS HAVING A DECREASED CELLULAR UPTAKE
    Publication number: 20170066813
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to modied Factor VIII molecules having decreased cellular uptake.
    Type: Application
    Filed: November 18, 2016
    Publication date: March 9, 2017
    Inventors: Henriet Meems, Alexander Benjamin Meijer, Koenraad Mertens, Ole Hvilsted Olsen, Kasper Lamberth, Peder Lisby Noerby, Laust Bruun Johnsen, Marianne Hjortnes Kjalke, Henning Ralf Stennicke, Johannes Jacobus Voorberg, Maartje Van Den Biggelaar
  • Factor VIII Molecules with Reduced VWF Binding
    Publication number: 20170020992
    Abstract: The present invention relates to a recombinant Factor VIII molecule, wherein said molecule has reduced vWF binding capacity, and wherein said molecule is covalently conjugated with at least one side group.
    Type: Application
    Filed: October 7, 2016
    Publication date: January 26, 2017
    Inventors: Gert Bolt, Bernd Peschke, Mikael Kofod-Hansen, Jens Buchardt, Henning Ralf Stennicke, Henrik Oestergaard, Marianne Kjalke, Eva H. Norling Olsen, Jens Jacob Hansen, Magali Zundel
  • Stabilized Factor VIII Variants
    Publication number: 20160264645
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to stabilized Factor VIII molecules conjugated with a half life extending moiety as well as use of such molecules.
    Type: Application
    Filed: June 1, 2016
    Publication date: September 15, 2016
    Inventors: Henrik Oestergaard, Marianne Kjalke, Ole Hvilsted Olsen, Lars Thim, Henning Ralf Stennicke
  • Conjugated Factor VIII Molecules
    Publication number: 20160222086
    Abstract: The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half-life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules.
    Type: Application
    Filed: August 20, 2015
    Publication date: August 4, 2016
    Inventors: Gert Bolt, Brian Berg Stidsen Vandahl, Lars Thim, Henning Ralf Stennicke, Thomas Dock Steenstrup, Shawn Defrees
  • Factor VIII variants having a decreased cellular uptake
    Patent number: 9321827
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to modied Factor VIII molecules having decreased cellular uptake.
    Type: Grant
    Filed: September 14, 2011
    Date of Patent: April 26, 2016
    Assignees: Novo Nordisk A/S, Sanquin Blood Supply Foundation
    Inventors: Henriet Meems, Alexander Benjamin Meijer, Koenraad Mertens, Ole Hvilsted Olsen, Kasper Lamberth, Peder Lisby Noerby, Laust Bruun Johnsen, Marianne Hjortnæs Kjalke, Henning Ralf Stennicke, Johannes Voorberg, Maartje Van Den Biggelaar
  • FACTOR VIII VARIANTS HAVING A DECREASED CELLULAR UPTAKE
    Publication number: 20160002314
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to modied Factor VIII molecules having decreased cellular uptake.
    Type: Application
    Filed: September 23, 2015
    Publication date: January 7, 2016
    Inventors: Henriet Meems, Alexander Benjamin Meijer, Koenraad Mertens, Ole Hvilsted Olsen, Kasper Lamberth, Peder Lisby Noerby, Laust Bruun Johnsen, Marianne Kjalke, Henning Ralf Stennicke, Johannes Jacobus Voorberg, Maartje Van Den Biggelaar
  • Factor VIII Molecules With Reduced VWF Binding
    Publication number: 20150376262
    Abstract: The present invention relates to a recombinant Factor VIII molecule, wherein said molecule has reduced vWF binding capacity, and wherein said molecule is covalently conjugated with at least one side group.
    Type: Application
    Filed: September 11, 2015
    Publication date: December 31, 2015
    Inventors: Bernd Peschke, Mikael Kofod-Hansen, Jens Buchardt, Henning Ralf Stennicke, Henrik Oestergaard, Marianne Kjalke, Eva H. Norling Olsen, Olsen, Jens Jacob Hansen
  • Conjugated factor VIII molecules
    Patent number: 9150848
    Abstract: The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules.
    Type: Grant
    Filed: May 8, 2014
    Date of Patent: October 6, 2015
    Assignee: Novo Nordisk A/s
    Inventors: Gert Bolt, Brian Berg Stidsen Vandahl, Lars Thim, Henning Ralf Stennicke, Thomas Dock Steenstrup, Shawn DeFrees
  • FACTOR VII CONJUGATES
    Publication number: 20150259665
    Abstract: The present invention relates to the conjugation of Factor VII polypeptides with heparosan polymers. The resultant conjugates may be used to deliver Factor VII, for example in the treatment or prevention of bleeding disorders.
    Type: Application
    Filed: October 15, 2013
    Publication date: September 17, 2015
    Inventors: Carsten Behrens, Henrik Oestergaard, Henning Ralf Stennicke
  • Selective modification of proteins
    Patent number: 8859731
    Abstract: A method of selectively introducing a substituent into a protein proximal to a binding site on the protein for a homing peptide, comprising: (a) contacting the protein with a compound comprising a homing peptide having the ability to bind to the binding site of the protein; and (b) allowing a moiety on the protein proximal to the binding site to react with the compound comprising the homing peptide, thereby to transfer the substituent G onto the protein.
    Type: Grant
    Filed: April 12, 2011
    Date of Patent: October 14, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Mikael Kofod-Hansen, Henning Ralf Stennicke, Soeren Oestergaard, Henrik Oestergaard
  • CONJUGATED FACTOR VIII MOLECULES
    Publication number: 20140242057
    Abstract: The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules.
    Type: Application
    Filed: May 8, 2014
    Publication date: August 28, 2014
    Applicant: Novo Nordisk A/S
    Inventors: Gert Bolt, Brian Berg Stidsen Vandahl, Lars Thim, Henning Ralf Stennicke, Thomas Dock Steenstrup, Shawn DeFrees
  • FACTOR VIII VARIANTS HAVING A DECREASED CELLULAR UPTAKE
    Publication number: 20140057848
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to modified Factor VIII molecules having decreased cellular uptake.
    Type: Application
    Filed: September 14, 2011
    Publication date: February 27, 2014
    Applicant: NOVO NORDISK A/S
    Inventors: Henriet Meems, Alexander Benjamin Meijer, Koenraad Mertens, Ole Hvilsted Olsen, Kasper Lamberth, Peder Lisby Noerby, Laust Bruun Johnsen, Marianne Hjortnæs Kjalke, Henning Ralf Stennicke, Johannes Voorberg, Maartje Van Den Biggelaar
  • Conjugated factor VIII molecules
    Patent number: 8536126
    Abstract: The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: September 17, 2013
    Assignee: Novo Nordisk A/S
    Inventors: Gert Bolt, Brian Berg Stidsen Vandahl, Lars Thim, Henning Ralf Stennicke, Thomas Dock Steenstrup, Shawn DeFrees
  • Conjugated Factor VIII Molecules
    Publication number: 20130189239
    Abstract: The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules.
    Type: Application
    Filed: February 26, 2009
    Publication date: July 25, 2013
    Applicant: Novo Nordisk A/S
    Inventors: Gert Bolt, Brian Berg Stidsen Vandahl, Lars Thim, Henning Ralf Stennicke, Thomas Dock Steenstrup, Shawn Defrees
  • STABILIZED FACTOR VIII VARIANTS
    Publication number: 20130183280
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to stabilized Factor VIII molecules conjugated with a half life extending moiety as well as use of such molecules.
    Type: Application
    Filed: July 6, 2011
    Publication date: July 18, 2013
    Applicant: NOVO NORDISK A/S
    Inventors: Henrik Oestergaard, Marianne Kjalke, Ole Hvilsted Olsen, Lars Thim, Henning Ralf Stennicke